In a study using actual data on hospitalizations and costs before and after PCV-10 vaccine was introduced in Brazil, an estimated 463,000 hospitalizations from all causes of pneumonia were prevented in persons less than 65 years of age over 5 years following introduction of the vaccine — saving an estimated US$147 million in hospitalization costs. Half of the costs averted were due to fewer hospitalizations in children under five, who were targeted for the vaccine, while the remaining half were due to fewer hospitalizations in persons 5-49 years of age, as a result of herd protection.
Full Citation:
Andrade AL, Afonso ET, Minamisava R et al.. 2017. Direct and indirect impact of 10-valent pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age groups in Brazil: A time-series analysis. PLoS One. 12(9).
Title of Article: Direct and indirect impact of 10-valent pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age groups in Brazil: A time-series analysis
Author(s): Andrade AL, Afonso ET, Minamisava R et al.
Publication Year: 2017
Publication Name: PLoS One
Publication Volume: 12(9)
Publication Source URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589174/pdf/pone.0184204.pdf
DOI (Digital Object Identifier): 10.1371/journal.pone.0184204
Topics: Economics & Return on Investment
Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia
Countries: Brazil
WHO Regions: Americas